Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Trastuzumab and Pertuzumab +/- Paclitaxel in HER2+/HR- Breast Cancer (ADAPT)
NCT01817452Phase 2Completed
- Sponsor
- Westdeutsche Studiengruppe
- Start
- Mar 2014
- Primary completion
- Jan 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab, pertuzumab in breast cancer, sponsored by Westdeutsche Studiengruppe. Started Mar 2014; status: completed.
02
Drugs
trastuzumabpertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01817452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01817452.